- Home
- BFRI vs PASG Comparison
BFRI vs PASG Comparison
Compare BFRI & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | PASG |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | 94 | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BFRI | PASG |
|---|---|---|
| Price | $1.19 | $4.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.75 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 393.6K | 36.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.36 | N/A |
| Revenue Next Year | $16.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $3.29 |
| 52 Week High | $1.27 | $20.00 |
Technical Indicators
Market Signals| Indicator | BFRI | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 46.26 |
| Support Level | $0.71 | $4.25 |
| Resistance Level | N/A | $5.04 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 74.55 | 52.94 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.